Join us for the ACC Delaware Chapter Meeting: ACC by the Sea for engaging live education sessions from local, regional, and national experts with Q&A real-time. The educational meeting includes topics of cardio obstetrics, lipids, amyloid, etc., and a chapter update from our Governor Dr. Vinay Hosmane. Participation in this event will earn CME/CNE/and MOC. We look forward to seeing you (IN-PERSON) September 25 - 26, 2026!

For more Information and Register: Delaware ACC By the Sea: 2026 Chapter Meeting

Download the Brochure: Brochure

Delaware Chapter of the American College of Cardiology


Our purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments.

ACC Live Courses

For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • JACC Late-Breaking Science Explores PET Imaging, HELIOS-B, DAPA ACT HF-TIMI 68 Analyses
    Late-breaking science presented at ESC Congress 2026 and simultaneously published in JACC Journals explore the performance of 124I-evuzamitide PET/MRI in patients with established or suspected cardiac amyloidosis (CA), treatment effect of vutrisiran by baseline tafamidis use, and impact of dapagliflozin on congestion in patients hospitalized for heart failure (HF).
  • TAVI PCI, ACASA-TAVI, TRIC-I-HF: New Answers in Structural Heart Care
    Three late-breaking trials presented at ESC Congress 2026 offer new insights into the management of structural heart disease and heart failure (HF), spanning coronary revascularization during TAVI, transcatheter treatment of tricuspid regurgitation, and post-TAVI antithrombotic therapy. Together, the TAVI PCI, ACASA-TAVI and TRIC-I-HF studies provide important evidence to help refine treatment strategies and improve patient […]
  • NOTION-4: Short-Term DOAC Therapy and Subclinical Leaflet Thickening Post TAVR
    A three-month direct oral anticoagulant (DOAC) regimen shortly after successful TAVR substantially reduced hypoattenuated leaflet thickening (HALT) during treatment vs. single antiplatelet therapy (SAPT) alone, based on findings from the NOTION-4 trial presented at ESC Congress 2026 and simultaneously published in JACC. However, researchers noted that this effect was diminished around nine months following discontinuation […]
  • TIME-HF: Nurse-Led, Mobile Health-Supported Collaborative Care Model Improves HF Outcomes in India
    A nurse-led collaborative care model that integrated mobile health improved overall survival and days out of the hospital among patients with heart failure with reduced ejection fraction (HFrEF) in India, based on findings from the TIME-HF trial presented at ESC Congress 2026 and simultaneously published in Circulation. Researchers highlight that this model may serve as […]
  • LUMINARA: Oral Relaxin Receptor Agonist AZD5462 in Treating Chronic HF
    The addition of AZD5462, an oral once-daily relaxin family peptide receptor 1 agonist, was well tolerated among individuals with well-treated chronic heart failure (HF), based on findings from LUMINARA presented at ESC Congress 2026 and simultaneously published in Circulation. In addition, researchers observed encouraging effects on cardiovascular hemodynamic measures across a wide range of left […]